Lung Research Tissue Bank (Version 4)

• Research type

  Research Tissue Bank

• IRAS ID

  289352

• Research summary

  Sheffield Lung Research Tissue Bank

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  21/NW/0026

• Date of REC Opinion

  11 Feb 2021

• REC opinion

  Favourable Opinion

• Data collection arrangements

  We wish to establish a lung tissue research bank in order to support a long-standing interest in respiratory diseases. We will obtain lung tissue from surgical cases. Consultant histopathologists will be responsible for the provision of lung tissue. The tissue that we receive would normally have been destroyed. Samples will be banked at the Sheffield Biorepository. Samples will be anonymised so it will not be possible to link the tissue to an individual. Data collected about a sample will also be stored anonymised on an extremely secure hard-drive created by computer services at Sheffield University. Access to this information will be restricted to two senior investigators. Potential participants will be sent a letter of invitation. Together with the letter, an information sheet, a short questionnaire and a consent form will be included. The participant then has an opportunity to read through any relevant material well in advance of attending hospital. The participant then has the choice of either signing the consent form in advance or when they attend hospital when we will be on hand to field any questions that they may have.

• Research programme

  We are interested in different types of lung cell and the triggers that activate these cells. Lung cell activation could contribute to respiratory diseases such as asthma, COPD and disease of lung blood vessels. We are also interested in establishing mechanisms by which established drugs used for respiratory disorders, such as inhalers, work on cells found in the lung. We are also interested in testing alternative drugs on these cells either to assess how the cells work or because some of these drugs may be of potential therapeutic benefit. Some of these drugs will, therefore, have been developed by the pharmaceutical industry. Overall, these studies will identify (a) how lung cells are activated and (b) new approaches to treating lung diseases. These studies have been supported by a range of funders including the pharmaceutical industry (Pfizer, Novartis, Takeda), charities (Asthma UK, British Heart Foundation), Research Councils (BBSRC) and overseas’ education ministries.

• Storage license

  12182

• RTBTitle

  Sheffield Lung Research Tissue Bank

• Establishment organisation

  University of Sheffield

• Establishment organisation address

  New Spring House

  231 Glossop Road

  Sheffield

  S10 2GW